These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. Sneller MC; Kopp WC; Engelke KJ; Yovandich JL; Creekmore SP; Waldmann TA; Lane HC Blood; 2011 Dec; 118(26):6845-8. PubMed ID: 22067383 [TBL] [Abstract][Full Text] [Related]
9. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo. Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157 [TBL] [Abstract][Full Text] [Related]
10. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation. Wu Z; Xu Y J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116 [TBL] [Abstract][Full Text] [Related]
12. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment. Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840 [TBL] [Abstract][Full Text] [Related]
13. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288 [TBL] [Abstract][Full Text] [Related]
14. Effect of Anti-IL-15 Administration on T Cell and NK Cell Homeostasis in Rhesus Macaques. DeGottardi MQ; Okoye AA; Vaidya M; Talla A; Konfe AL; Reyes MD; Clock JA; Duell DM; Legasse AW; Sabnis A; Park BS; Axthelm MK; Estes JD; Reiman KA; Sekaly RP; Picker LJ J Immunol; 2016 Aug; 197(4):1183-98. PubMed ID: 27430715 [TBL] [Abstract][Full Text] [Related]
15. IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation. Van den Bergh JM; Lion E; Van Tendeloo VF; Smits EL Pharmacol Ther; 2017 Feb; 170():73-79. PubMed ID: 27777088 [TBL] [Abstract][Full Text] [Related]
16. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model. Zhao M; Luo M; Xie Y; Jiang H; Cagliero C; Li N; Ye H; Wu M; Hao S; Sun T; Yang H; Zhang M; Lin T; Lu H; Zhu J Biomed Pharmacother; 2019 Apr; 112():108677. PubMed ID: 30798123 [TBL] [Abstract][Full Text] [Related]
17. Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques. Bergamaschi C; Watson DC; Valentin A; Bear J; Peer CJ; Figg WD; Felber BK; Pavlakis GN Cytokine; 2018 Aug; 108():213-224. PubMed ID: 29402721 [TBL] [Abstract][Full Text] [Related]
18. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models. Guo S; Smeltz RB; Nanajian A; Heller R Front Immunol; 2020; 11():614667. PubMed ID: 33628206 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720 [TBL] [Abstract][Full Text] [Related]
20. Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies. Rosenthal MA; Dennis D; Liebes L; Furmanski P; Caron D; Garrison L; Wiprovnick J; Peace D; Oratz R; Speyer J; Chachoua A J Immunother; 1998 Sep; 21(5):371-8. PubMed ID: 9789199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]